The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
During the 24th Meeting of the European Hematology Association (EHA) in Amsterdam, NL, Gail Roboz, Weill Cornell Medicine and The Weill Medical College of Cornell University, New York, US, presented an updated analysis from the first-in-human phase I trial of AMV564, a novel bispecific CD33/CD3 targeted immunotherapeutic, which was tested in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML).
Professor (Prof.) Roboz highlighted that relapse is still very common and a prominent problem in AML, with patients who relapse generally succumbing to the disease within 1 year. She noted that chemotherapeutic agents, and hypomethylating agents, are equally unsuccessful with overall response rates (ORRs) ranging between 18% and 41% in selected studies. This, therefore, means that the AML field is looking for novel agents that can counteract the existing dismal outcome. One such area of novel agents gaining a lot of interest is immunotherapy.
AMV564 is a bivalent, bispecific CD33/CD3 T-cell engager;
Characteristic
Total (N)
33
Median age (years)
71.5 (24–85)
ECOG score ≥2
12%
Secondary AML
73%
Prior allo-HSCT
9%
Prior intensive chemotherapy
64%
MRC cytogenetic risk – unfavorable
58%
Enrollment bone marrow (BM) blasts
30% (3%–96%)
Baseline white blood cell count (x109/L)
2.1 (0.2–13.8)
Target dose level (mcg)
Number of cycles
Best response (throughout cycles)
Response at last assessment
100
5
SD
SD
100
2
PR
PR
150
6
CRi
SD
150
2
SD
SD
200
2
CR
SD
200
2
SD
SD
250
2
SD
SD
A new lead-in dose regimen, without steroids, is being used to allow for continued dose escalation as shown in Table 3.
Table 3: Lead-in dosing scheduleLead-in dose (mcg)*
Target dose (mcg)
Cycles
Grade 1
Grade 2
Not applicable
15
30
3
1
15
100
21
4
0
15–100
150
4
2
0
15–100
200
3
0
2
15–100
250
1
0
1
15–30–100–150–200
250
3
0
1
*In patients who received 15mcg and then 100 mcg, they received 15mcg for 3 days followed by 100mcg for 3 days. In the last patient in the table, 15mcg, 30mcg, 100mcg, 150mcg and 200mcg were given for 1 day at a time.
Prof. Roboz, and fellow authors on the study, concluded that AMV564 was well-tolerated up to doses of 250mcg, with no DLTs observed to date. There were only limited grade 1 and 2 CRS events, and a lead-in dose schedule is now being utilized to continue the escalation up to 450mcg. Some responses and stabilization of the disease for up to 7 months were observed.
References